Safety of ovarian preservation for premenopausal patients with FIGO stage I grade 2 and 3 endometrioid endometrial adenocarcinoma

被引:0
|
作者
Nasioudis, Dimitrios [1 ]
Mastroyannis, Spyridon A. [1 ]
Ko, Emily M. [1 ]
Haggerty, Ashley F. [1 ]
Cory, Lori [1 ]
Giuntoli, Robert L., II [1 ]
Kim, Sarah H. [1 ]
Latif, Nawar A. [1 ]
机构
[1] Univ Penn, Div Gynecol Oncol, Philadelphia, PA 19104 USA
关键词
endometrial neoplasms; ovary; hysterectomy; YOUNG-WOMEN; CANCER; INVOLVEMENT; METASTASIS; MALIGNANCY; GUIDELINES; IMPACT; RISK;
D O I
10.1136/ijgc-2022-003450
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective To investigate the utilization and outcomes of ovarian preservation for premenopausal patients with International Federation of Gynecology and Obstetrics (FIGO) stage I grade 2 and 3 endometrioid endometrial carcinoma undergoing hysterectomy. Methods The National Cancer Database was accessed; patients aged <= 45 years diagnosed between January 2004 and December 2015 with FIGO stage I grade 2 or 3 endometrioid endometrial carcinoma, who underwent hysterectomy with or without bilateral salpingo-oophorectomy and had at least 1 month of follow-up, were identified. Overall survival was assessed following generation of Kaplan-Meier curves and compared with the log-rank test. A Cox model was constructed to control for a priori selected variables. Results A total of 2941 patients who met the inclusion criteria were identified; 200 (6.8%) patients did not undergo bilateral salpingo-oophorectomy. Rate of ovarian preservation was comparable between patients with grade 2 (n=163, 6.6%) and grade 3 (n=37, 7.7%) tumors (p=0.38). Patients who did not undergo bilateral salpingo-oophorectomy were younger (median 39 vs 41 years, p<0.001) and less likely to undergo surgical lymph node assessment (52% vs 76.2%, p<0.001). There was no difference in overall survival between patients who did and did not undergo bilateral salpingo-oophorectomy (p=0.94); 5 year overall survival rates were 96.6% and 97%, respectively. After controlling for confounders, including tumor grade, ovarian preservation was not associated with worse overall survival (HR 0.92, 95% CI 0.47 to 1.84). Conclusions For patients with grade 2 and 3 FIGO stage I endometrioid carcinoma undergoing hysterectomy, ovarian preservation is rarely performed while no clear detrimental effect on overall survival was found.
引用
收藏
页码:1355 / 1360
页数:6
相关论文
共 50 条
  • [1] Safety of ovarian preservation for premenopausal patients with FIGO stage I grade 2 and 3 endometrioid endometrial adenocarcinoma
    Nasioudis, Dimitrios
    Byrne, Maureen
    Mastroyannis, Spyridon
    Ko, Emily
    Haggerty, Ashley
    Latif, Nawar
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 162 : S270 - S270
  • [2] The Safety of Ovarian Preservation in Stage I Endometrial Endometrioid Adenocarcinoma Based on Propensity Score Matching
    Hou, Ting
    Sun, Yidi
    Li, Junyi
    Liu, Chenglin
    Wang, Zhen
    Li, Yixue
    Lu, Yuan
    [J]. COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2017, 20 (07) : 647 - 655
  • [3] Is adjuvant radiotherapy necessary for FIGO stage 1a grade 2 endometrial endometrioid adenocarcinoma?
    Inan, Abdurrahman Hamdi
    Ersoy, Gulcin Sahin
    Yildinm, Yusuf
    Gurbuz, Tutku
    Kebapcilar, Ayse Gul
    Hanhan, Merih
    [J]. JOURNAL OF THE TURKISH-GERMAN GYNECOLOGICAL ASSOCIATION, 2015, 16 (03) : 153 - 157
  • [4] Histologic Patterns of Myometrial Invasion in FIGO Grade 2 Endometrioid Endometrial Adenocarcinoma
    Lin, D. I.
    Winham, W. M.
    Stone, P. J.
    Quick, C. M.
    Nucci, M. R.
    [J]. LABORATORY INVESTIGATION, 2012, 92 : 283A - 283A
  • [5] Histologic Patterns of Myometrial Invasion in FIGO Grade 2 Endometrioid Endometrial Adenocarcinoma
    Lin, D. I.
    Winham, W. M.
    Stone, P. J.
    Quick, C. M.
    Nucci, M. R.
    [J]. MODERN PATHOLOGY, 2012, 25 : 283A - 283A
  • [6] SAFETY OF OVARIAN PRESERVATION IN PREMENOPAUSAL WOMEN WITH ENDOMETRIOID ENDOMETRIAL CANCER CLINICALLY CONFINED TO THE UTERUS
    Ju, U. C.
    Kim, S. M.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A331 - A331
  • [7] The role of adjuvant chemotherapy in FIGO stage IB grade 3 endometrial endometrioid adenocarcinoma treated with surgery and postoperative radiotherapy
    Reshko, Leonid
    Gaskins, Jeremy
    Dryden, Sara
    Metzinger, Daniel
    Todd, Sarah
    Eldredge-Hindy, Harriet
    Silva, Scott
    [J]. GYNECOLOGIC ONCOLOGY, 2021, 162 : S303 - S304
  • [8] Role of adjuvant chemotherapy in patients with FIGO stage IB grade 3 endometrial endometrioid adenocarcinoma treated with surgery and post-operative radiotherapy
    Reshko, Leonid B.
    Gaskins, Jeremy T.
    Dryden, Sara M.
    Metzinger, Daniel S.
    Todd, Sarah L.
    Eldredge-Hindy, Harriet B.
    Silva, Scott R.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (05) : 694 - 701
  • [9] Safety of ovarian preservation in premenopausal women with stage I uterine sarcoma
    Nasioudis, Dimitrios
    Chapman-Davis, Eloise
    Frey, Melissa
    Holcomb, Kevin
    [J]. JOURNAL OF GYNECOLOGIC ONCOLOGY, 2017, 28 (04)
  • [10] Clinical behavior of FIGO stage I endometrioid endometrial adenocarcinoma diagnosed as high-grade on preoperative biopsy and low-grade on hysterectomy specimen
    Schlappe, B.
    Schiavone, M. B.
    DeLair, D.
    Ducie, J. A.
    Eriksson, A. G. Z.
    Zivanovic, O.
    Makker, V.
    Soslow, R. A.
    Abu-Rustum, N. R.
    Leitao, M. M.
    [J]. GYNECOLOGIC ONCOLOGY, 2017, 145 : 102 - 102